Cardiooncology-usefulness of cardiac MRI : Inflammation, fibrosis, outcome
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
BACKGROUND: With rapidly increasing survival chances of cancer patients, the potential side effects of cancer therapeutics are increasingly relevant and a potentially lifelong issue. If cardiotoxic effects are not detected at a reversible stage, this might result in irreversible heart failure.
OBJECTIVES: This article will portray the current state of knowledge on the use of cardiac magnetic resonance imaging (cardiac MRI) in the field of cardio-oncology. The aim is to provide an overview of the advantages of cardiac MRI to determine myocardial function and analyze inflammatory or fibrotic myocardial changes.
MATERIALS AND METHODS: Current studies on this topic were collected and evaluated. Expert recommendations from various position papers were reviewed and summarized. Lastly, an MRI protocol to assess potential cardiotoxic effects of cancer therapeutics was discussed.
RESULTS: Up to 20% of patients are reported to suffer from cancer therapeutics-related cardiac dysfunction (CTRCD). Especially those with cardiovascular risk factors should receive pre- and posttherapeutic monitoring of heart function. Cardiac MRI is currently suggested as an imaging tool to analyze myocardial function if echocardiographic assessment is insufficient. However, cardiac MRI is also an excellent method for additional tissue analysis.
CONCLUSION: Current consensus statements recommend cardiac MRI as optional in cases where echocardiography image quality is not adequate. Nevertheless, patients with reduced heart function on echocardiography might benefit from early assessment of inflammatory or fibrotic changes due to CTRCD using cardiac MRI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Radiologie (Heidelberg, Germany) - 62(2022), 11 vom: 25. Nov., Seite 941-946 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Kardioonkologie – was leistet die MRT? : Inflammation, Fibrose, Outcome |
|---|
| Beteiligte Personen: |
Erley, Jennifer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer therapeutics-related cardiac dysfunction |
|---|
| Anmerkungen: |
Date Completed 31.10.2022 Date Revised 31.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00117-022-01055-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344879674 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344879674 | ||
| 003 | DE-627 | ||
| 005 | 20231226023802.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00117-022-01055-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344879674 | ||
| 035 | |a (NLM)35969245 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Erley, Jennifer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiooncology-usefulness of cardiac MRI |b Inflammation, fibrosis, outcome |
| 246 | 3 | 3 | |a Kardioonkologie – was leistet die MRT? : Inflammation, Fibrose, Outcome |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2022 | ||
| 500 | |a Date Revised 31.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a BACKGROUND: With rapidly increasing survival chances of cancer patients, the potential side effects of cancer therapeutics are increasingly relevant and a potentially lifelong issue. If cardiotoxic effects are not detected at a reversible stage, this might result in irreversible heart failure | ||
| 520 | |a OBJECTIVES: This article will portray the current state of knowledge on the use of cardiac magnetic resonance imaging (cardiac MRI) in the field of cardio-oncology. The aim is to provide an overview of the advantages of cardiac MRI to determine myocardial function and analyze inflammatory or fibrotic myocardial changes | ||
| 520 | |a MATERIALS AND METHODS: Current studies on this topic were collected and evaluated. Expert recommendations from various position papers were reviewed and summarized. Lastly, an MRI protocol to assess potential cardiotoxic effects of cancer therapeutics was discussed | ||
| 520 | |a RESULTS: Up to 20% of patients are reported to suffer from cancer therapeutics-related cardiac dysfunction (CTRCD). Especially those with cardiovascular risk factors should receive pre- and posttherapeutic monitoring of heart function. Cardiac MRI is currently suggested as an imaging tool to analyze myocardial function if echocardiographic assessment is insufficient. However, cardiac MRI is also an excellent method for additional tissue analysis | ||
| 520 | |a CONCLUSION: Current consensus statements recommend cardiac MRI as optional in cases where echocardiography image quality is not adequate. Nevertheless, patients with reduced heart function on echocardiography might benefit from early assessment of inflammatory or fibrotic changes due to CTRCD using cardiac MRI | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer therapeutics-related cardiac dysfunction | |
| 650 | 4 | |a Cardiac magnetic resonance imaging | |
| 650 | 4 | |a Cardio-oncology | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a Myocarditis | |
| 700 | 1 | |a Beitzen-Heineke, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Tahir, Enver |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiologie (Heidelberg, Germany) |d 2022 |g 62(2022), 11 vom: 25. Nov., Seite 941-946 |w (DE-627)NLM338822127 |x 2731-7056 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2022 |g number:11 |g day:25 |g month:11 |g pages:941-946 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00117-022-01055-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2022 |e 11 |b 25 |c 11 |h 941-946 | ||